Bladder Cancer Paradigm Expanding to Include Immunotherapy Combos, Targeted Therapies – OncLive
OncLive |
Bladder Cancer Paradigm Expanding to Include Immunotherapy Combos, Targeted Therapies
OncLive The bladder cancer community has generated excitement with 5 monotherapy approvals for PD-1/PD-L1 inhibitors within the last year, including nivolumab (Opdivo), durvalumab (Imfinzi), avelumab (Bavencio), atezolizumab (Tecentriq), and pembrolizumab … |
